此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

基于算法的双联抗血小板治疗定制以改善经皮冠状动脉介入治疗后的结果 (TAILOR-DAPT)

2026年10月30日 更新者:Insel Gruppe AG, University Hospital Bern

The use of aspirin combined with a P2Y12 inhibitor (dual antiplatelet therapy, DAPT) represents the standard of care for patients undergoing percutaneous coronary intervention (PCI) with stent implantation. The TAILOR-DAPT trial aims to investigate the benefits of a score-based decision-making algorithm to guide DAPT duration compared to a standard-of-care DAPT duration without the use of risk scores in patients undergoing PCI.

研究概览

详细说明

Background:

The use of aspirin combined with a P2Y12 inhibitor (dual antiplatelet therapy, DAPT) represents the standard of care for patients undergoing percutaneous coronary intervention (PCI) with stent implantation. European guidelines recommend to implement risk scores to guide the duration of DAPT after stent implantation (class IIb, level of evidence A). However, its adoption rate remains exceedingly low in daily clinical practice in part due to the lack of direct evidence obtained from a randomized controlled trial supporting this strategy.

Aim:

Using a pragmatic study-design, the investigators aim to determine the efficacy and safety of an algorithm-guided strategy for DAPT duration compared to a standard-of-care DAPT without the use of risk scores in patients undergoing PCI with stent implantation.

Methodology:

This investigator-initiated, single-blind, randomized trial will include a total of 2788 patients aged ≥18 years undergoing PCI with stent implantation. Main exclusion criteria are peri-procedural complications potentially affecting DAPT duration. The study will be nested into a well-running registry to minimize study-related costs (pragmatic trial approach). Patients will be randomized to an algorithm-guided DAPT group or a standard-of-care DAPT group in a 1:1 fashion. In the algorithm-guided group, DAPT duration will be determined according to the PRECISE-DAPT score (≥25 or <25) / Precise-HBR score (≥23 or <23), PCI complexity, and clinical presentation (acute or chronic coronary syndromes). In the standard-of-care DAPT group, treatment duration is at the operator's discretion. The primary endpoint is a composite of net adverse clinical events (NACE) defined as all-cause death, spontaneous myocardial infarction, stroke, definite stent thrombosis or Bleeding Academic Research Consortium (BARC) 2, 3, or 5 bleeding at 1 year.

Potential significance:

This will be the first study evaluating the impact of a score-based decision-making algorithm integrating bleeding and ischemic risks for DAPT duration among patients undergoing PCI. The hypothesis is that the proposed simple decision-making algorithm minimizes bleeding risk and maximizes ischemic benefit compared to a standard-of-care DAPT regimen. Prospective data obtained from a pragmatic randomized controlled trial embedded into an on-going, well-managed PCI registry database may further enhance the adoption rate of such a strategy in clinical practice.

研究类型

介入性

注册 (估计的)

2788

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

学习地点

      • Roma、意大利、00184
      • Banja Luka、波斯尼亚和黑塞哥维那、78000
        • 招聘中
        • University Clinical Center of the Republic of Srpska
        • 接触:
        • 首席研究员:
          • Bojan Stanetic, MD, PhD
      • Bern、瑞士、3010
        • 招聘中
        • Department of Cardiology, Bern University Hospital
        • 首席研究员:
          • Miklos Rohla, MD, PhD
    • Canton of Bern
      • Biel/Bienne、Canton of Bern、瑞士、2501
        • 招聘中
        • Kardiologie Spitalzentrum Biel
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. PCI with drug eluting stent (DES) implantation
  2. Age ≥18 years
  3. Ability to sign informed consent before any study-specific procedure

Exclusion Criteria:

  1. Planned staged PCI (Patients can be enrolled after complete coronary revascularization with no remaining lesions intended for treatment. Patients who have or develop an indication for percutaneous valve intervention can undergo treatment 30 days after full coronary revascularization)
  2. Indication for oral anticoagulation
  3. Peri-procedural complication which affects DAPT regimen based on the operator's opinion (e.g. untreated flow-limiting angiographic complication, intraprocedural stent thrombosis, persistent vessel occlusion/no-reflow at the end of the procedure, major side-branch occlusion, puncture-site related or other relevant bleeding)
  4. Treatment for stent thrombosis at qualifying PCI or within 1 year prior to qualifying PCI
  5. Active bleeding requiring medical attention at qualifying PCI
  6. The presence of hemodynamic instability (persistent systolic blood pressure below 90mmHg, continuous infusions of catecholamines, clinical signs of hypoperfusion and/or use of percutaneous left ventricular assist devices)
  7. Life expectancy less than 1 year
  8. Women of childbearing potential (i.e. fertile, following menarche and until becoming post-menopausal unless permanently sterile)
  9. Planned surgery within the next 3 months
  10. Contraindication or known allergy against aspirin or P2Y12 inhibitors (clopidogrel, ticagrelor, and prasugrel)
  11. Participation in a drug trial

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:双倍的

武器和干预

参与者组/臂
干预/治疗
实验性的:Intervention

Algorithm-guided DAPT duration

PRECISE-DAPT score ≥25 / PRECISE-HBR Score ≥23

  • Chronic Coronary Syndromes (CCS): Aspirin + clopidogrel for 1 month, followed by clopidogrel monotherapy
  • Acute Coronary Syndromes (ACS): Aspirin + ticagrelor for 1 month, followed by ticagrelor monotherapy

PRECISE-DAPT score <25 / PRECISE-HBR Score <23:

  • Non-complex CCS: Aspirin + clopidogrel for 6 months, followed by clopidogrel monotherapy
  • Non-complex ACS: Aspirin + potent P2Y12 inhibitor for 6 months, followed by potent P2Y12 inhibitor monotherapy
  • Complex CCS or ACS: Aspirin + P2Y12 inhibitor for 12 months, followed by P2Y12 inhibitor monotherapy (potent P2Y12 inhibitor mandatory for ACS)
有源比较器:Standard

Standard-of-care DAPT duration

DAPT strategy at the operators´ discretion in accordance with applicable guidelines

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Net adverse clinical events (NACE)
大体时间:1 year

All-cause death, spontaneous myocardial infarction, definite stent thrombosis, stroke or non-access site related BARC 2, 3 or 5 bleeding

1 year

次要结果测量

结果测量
措施说明
大体时间
靶血管血运重建
大体时间:1年
1年
确定的支架内血栓形成
大体时间:1年
1年
心肌梗塞
大体时间:1年
1年
任何血运重建
大体时间:1年
1年
中风
大体时间:1年
1年
靶病变血运重建
大体时间:1年
1年
心血管死亡
大体时间:1年
1年
全因死亡
大体时间:1年
1年
靶血管心肌梗死
大体时间:1年
1年
非靶血管血运重建
大体时间:1年
1年
短暂性脑缺血发作
大体时间:1年
1年
自发性心肌梗死
大体时间:1年
1年
Major adverse cardiovascular events (MACE)
大体时间:1 year

Cardiovascular death, spontaneous myocardial infarction, definite stent thrombosis or stroke

1 year
Major or clinically relevant non-major bleeding
大体时间:1 year

Non-access site related Bleeding Academic Research Consortium (BARC) 2, 3 or 5 bleeding

1 year
Major bleeding
大体时间:1 year

Non-access site related Bleeding Academic Research Consortium (BARC) 3 or 5 bleeding

1 year
Any non-access site related Bleeding Academic Research Consortium (BARC) bleeding
大体时间:1 year
1 year
Target lesion failure
大体时间:1 year

Cardiac death, target-vessel myocardial infarction or target lesion revascularization

1 year
Adherence to DAPT
大体时间:1 year

According to the TAILOR-DAPT modified Non-adherence Academic Research Consortium (NARC) classification

1 year
Adherence to DAPT
大体时间:1 year

According to the traditional classification (Adherent≥80% of the time from randomization to intended DAPT cessation date)

1 year

其他结果措施

结果测量
措施说明
大体时间
Net adverse clinical events (NACE)
大体时间:24 months

All-cause death, spontaneous myocardial infarction, definite stent thrombosis, stroke or Bleeding Academic Research Consortium (BARC) 2, 3 or 5 bleeding

24 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 学习椅:Lorenz Räber, MD, PhD、Department of Cardiology, Bern University Hospital, Bern, Switzerland
  • 首席研究员:Miklos Rohla, MD, PhD、Department of Cardiology, Bern University Hospital, Bern, Switzerland

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2023年6月27日

初级完成 (估计的)

2029年12月1日

研究完成 (估计的)

2030年12月1日

研究注册日期

首次提交

2023年2月8日

首先提交符合 QC 标准的

2023年2月8日

首次发布 (实际的)

2023年2月17日

研究记录更新

最后更新发布 (实际的)

2026年11月3日

上次提交的符合 QC 标准的更新

2026年10月30日

最后验证

2026年10月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅